Options
Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles
Author(s)
Date Issued
2017-10
Abstract
Buccal delivery of macromolecules (biologics) sets a great challenge for researchers. Although several niche small molecule products have been approved as simple sprays, tablets and oral films, it is not simply a case of adapting existing technologies to biologics. Buccal delivery of insulin has reached clinical trials with two approaches: oromucosal sprays of the peptide with permeation enhancers, and embedded gold nanoparticles in a dissolvable film. However, neither of these approaches have led to FDA approvals likely due to poor efficacy, submaximal peptide loading in the dosage form, and to wide intra-subject variability in pharmacokinetics and pharmacodynamics. It is likely however that printed film designs with lower molecular weight stable biotech payloads including lipophilic glucagon-like 1 (GLP-1) agonists and macrocycles with long half-lives will generate greater efficacy than was achieved to date for insulin..
Sponsorship
Science Foundation Ireland
Other Sponsorship
Fondo de Investigación Avanzado en Areas Prioritarias (FONDAP)
Fondo Nacional de Desarrollo CientÃfico y Tecnológico (FONDECYT)
Type of Material
Journal Article
Publisher
Elsevier
Journal
Current Opinion in Pharmacology
Volume
36
Start Page
22
End Page
28
Copyright (Published Version)
2017 Elsevier
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
Owning collection
Scopus© citations
72
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Views
1011
Last Month
1
1
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Downloads
695
Acquisition Date
Mar 28, 2024
Mar 28, 2024